Geriatric Population COVID-19 Observational Study (GEROCOVIDobs)
NCT ID: NCT04379440
Last Updated: 2020-05-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1500 participants
OBSERVATIONAL
2020-04-25
2020-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Epidemiological Observatory on the Health Conditions of Inpatients Aged 65 or Older at the INRCA Research Hospitals
NCT01397682
Prognosis of Geriatric Patients 1 Year After Hospitalization for COVID-19
NCT05261061
Neuropsychological Assessment Of The Oldest-Old Population.(NEUROPSIC-GR)
NCT05481749
Geriatric Care for Older People Hospitalised for COVID-19
NCT04947943
Identification of Frailty Predictors of Adverse Health Outcomes in Community-dwelling Individuals Aged 50 and Over
NCT04603144
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The GeroCovid e-registry is intended to track Covid-19 pandemic impact on the general geriatric population and on age/care-setting related sub-populations.
The analysis of results is expected to facilitate the adoption of optimal standard of geriatric care during the pandemic.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
" Acute Ward Patients " care setting cohort
Acute Ward Hospitalised patients with suspected or known SARS-CoV-2 infection
No interventions assigned to this group
" Nursing Homes (RSA) " care setting cohort
Nursing Home Resident Older Adult suffering from Suspected or known SARS-CoV-2 infection
No interventions assigned to this group
" Home and Outpatients' Care " cohort
Outpatients at risk of SARS-CoV-2 infection
No interventions assigned to this group
" Dementia Outpatients " cohort
Outpatients suffering from Dementia according to NIA-AA criteria, at risk of SARS-CoV-2 infection and on Treatment with anti-cholinesterase- dugs and/or anti-psychotics
No interventions assigned to this group
" At home " cohort
Outpatients at risk of SARS-CoV-2 infection
No interventions assigned to this group
" Outcomes " cohort
Age≥65 years as target population Hospitalised patients diagnosed with SARS-CoV-2 infection
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Hospitalised patients
2. Suspected or known SARS-CoV-2 infection
2. Applying only to the "Nursing Homes (RSA)" cohort:
1. Nursing Home Resident Older Adults
2. Suspected or known SARS-CoV-2 infection
3. Applying only to the" Home and outpatients' care " cohort:
a. Outpatients at risk of SARS-CoV-2 infection
4. Applying only to the" Dementia outpatients " cohort:
1. Outpatients suffering from dementia according to NIA-AA criteria
2. At risk of SARS-CoV-2 infection
3. Ongoing treatment with anti-cholinesterase- dugs and/or anti-psychotics
5. Applying only to the" At home " cohort:
a. Outpatients at risk of SARS-CoV-2 infection
6. Applying only to the " Outcomes " cohort:
1. Age≥65 years
2. Hospitalised patients diagnosed with SARS-CoV-2 infection
Exclusion Criteria
2. Lack of a signed declaration by the responsible physician stating that no explicit opt-out advanced directives by the subject were known to be in place at the moment of inclusion if it had been impossible to inform the patient due to her/his state of consciousness and/or awareness of disease condition.
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Italian Society of Gerontology and Geriatrics
UNKNOWN
BLUECOMPANION FRANCE
UNKNOWN
BLUECOMPANION LTD
UNKNOWN
Raffaele Antonelli Incalzi
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Raffaele Antonelli Incalzi
Full Professor in Internal Medicine, Director of Geriatrics Department and Acting Director of Chronic Diseases Department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Raffaele Antonelli Incalzi, M.D.
Role: PRINCIPAL_INVESTIGATOR
Policlinico Campus Bio-Medico
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
RSA La Quiete
Castiglione Cosentino, Calabria, Italy
ASP Catanzaro
Catanzaro Lido, Calabria, Italy
AOU Ferrara
Ferrara, Emilia-Romagna, Italy
Policlinico Campus Bio-Medico
Rome, Roma, Italy
AOU Careggi
Florence, Tuscany, Italy
AOU Pisana Geriatria
Pisa, Tuscany, Italy
Ospedale di Comunita' ULSS 6 Euganea- COVID Center
Camposampiero, Veneto, Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Gareri P, Trevisan C, Abbatecola AM, Malara A, Incalzi RA. Efficacy of OM-85 in Recurrent Respiratory Tract Infections. Rev Recent Clin Trials. 2023;18(3):223-227. doi: 10.2174/1574887118666230518112806.
Trevisan C, Remelli F, Fumagalli S, Mossello E, Okoye C, Bellelli G, Coin A, Malara A, Gareri P, Monzani F, Del Signore S, Zia G, Antonelli Incalzi R, Volpato S; GeroCovid Acute Ward Working Group. COVID-19 as a Paradigmatic Model of the Heterogeneous Disease Presentation in Older People: Data from the GeroCovid Observational Study. Rejuvenation Res. 2022 Jun;25(3):129-140. doi: 10.1089/rej.2021.0063. Epub 2022 Jun 6.
Okoye C, Finamore P, Bellelli G, Coin A, Del Signore S, Fumagalli S, Gareri P, Malara A, Mossello E, Trevisan C, Volpato S, Zia G, Monzani F, Incalzi RA. Computed tomography findings and prognosis in older COVID-19 patients. BMC Geriatr. 2022 Mar 1;22(1):166. doi: 10.1186/s12877-022-02837-7.
Fumagalli S, Trevisan C, Del Signore S, Pelagalli G, Fumagalli C, Herbst A, Volpato S, Gareri P, Mossello E, Malara A, Monzani F, Okoye C, Coin A, Bellelli G, Zia G, Ungar A, Ranhoff AH, Antonelli Incalzi R; GeroCovid Working Group. Atrial fibrillation and COVID-19 in older patients: how disability contributes to shape the risk profile. An analysis of the GeroCovid registry. Aging Clin Exp Res. 2022 Jan;34(1):249-256. doi: 10.1007/s40520-021-02008-5. Epub 2021 Oct 30.
Trevisan C, Del Signore S, Fumagalli S, Gareri P, Malara A, Mossello E, Volpato S, Monzani F, Coin A, Bellelli G, Zia G, Ranhoff AH, Antonelli Incalzi R; GeroCovid Working Group. Assessing the impact of COVID-19 on the health of geriatric patients: The European GeroCovid Observational Study. Eur J Intern Med. 2021 May;87:29-35. doi: 10.1016/j.ejim.2021.01.017. Epub 2021 Jan 31.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GC01-Obs
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.